Compare IRWD & AMCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRWD | AMCX |
|---|---|---|
| Founded | 1998 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Cable & Other Pay Television Services |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 586.6M | 492.0M |
| IPO Year | 2009 | 2011 |
| Metric | IRWD | AMCX |
|---|---|---|
| Price | $3.47 | $9.20 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 4 | 8 |
| Target Price | $6.10 | ★ $9.67 |
| AVG Volume (30 Days) | ★ 1.6M | 557.2K |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1400.00 | 132.55 |
| EPS | ★ 0.55 | N/A |
| Revenue | $298,276,000.00 | ★ $2,311,801,000.00 |
| Revenue This Year | $59.19 | $5.07 |
| Revenue Next Year | $4.80 | N/A |
| P/E Ratio | $6.46 | ★ N/A |
| Revenue Growth | ★ 8.88 | N/A |
| 52 Week Low | $1.47 | $6.47 |
| 52 Week High | $5.78 | $12.93 |
| Indicator | IRWD | AMCX |
|---|---|---|
| Relative Strength Index (RSI) | 37.03 | 19.79 |
| Support Level | $3.04 | $9.02 |
| Resistance Level | $3.96 | $10.58 |
| Average True Range (ATR) | 0.18 | 0.34 |
| MACD | -0.01 | -0.16 |
| Stochastic Oscillator | 11.97 | 1.91 |
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
AMC Global Media owns several linear TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network,reached 55 million pay TV households in the US at the end of 2025. The firm also had nearly 10.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.